Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05227937

Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study

The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infection (UTI) with a single intramuscular (IM (into the arm)) or intravenous (IV (into the vein)) shot of amikacin, rather than having to go to the pharmacy to pick up a prescription for antibiotics, and then take antibiotics for 3-7 days. A single dose of amikacin has been demonstrated to be safe, effective and well tolerated in other studies, but some patients may decline to participate because they do not wish to have an IV or IM shot, or because they don't want to speak on the phone with a research assistant three times over the next 30 days.

Recruiting

Interested in participating?

Request Info

Key information

Age range

14 year–110 year

Sex eligibility

Female

Study type

Observational

Primary location

Maimonides Medical Center

Brooklyn, New York, 11219, United States

Location status: Recruiting

Location contact

Antonios Likourezos, MA, MPH

CONTACT

[email protected]

Reuben Strayer, MD

CONTACT

[email protected]

About this study

he study is a prospective open-label cohort study that seeks to enroll 75 ED patients diagnosed with uncomplicated cystitis. Enrolled patients will be treated with a single dose of amikacin. The primary endpoint is clinical cure at 3 days. We chose a non-comparative design as our treatment strategy is literature- and guideline- supported; our goal is demonstrate that it is feasible to execute this approach out of the emergency department. Urine culture is not recommended in the in the initial management of patients with uncomplicated UTI treated in emergency or primary care settings.3

Data Collection Procedures: Patients will be enrolled as a convenience sample by the research team. The investigators will determine eligibility, approach the ED clinical team, then approach and consent the patient.

If consented, patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients >120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.

The study measurements at enrollment are age, PMH, meds, allergies, symptoms, and symptom duration as well as urinalysis results, amikacin dose and route. Telephone follow-up at 3, 7, and 30 days will include the following data points: symptom resolution: (complete resolution / mostly better / a little better / same / worse); any new symptoms; any provider visits since index visit (if any visits, describe).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • female emergency medicine patients
  • ≥14 years of age
  • uncomplicated urinary tract infection
  • a primary urinary complaint and nitrite-positive urine.

Exclusion criteria

  • pregnancy
  • abnormal genitourinary tract
  • recent urinary tract instrumentation
  • immunosuppression
  • CrCl < 25 mL/min
  • evidence of pyelonephritis or sepsis
  • any antibiotic treatment within 30 days
  • not available for phone follow-up in 3, 7, and 30 days
  • requires admission to the hospital
  • abnormal mental status.

Treatment and study plan

Amikacin

Drug

patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients >120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.

Primary outcomes

  1. Resolution of Urinary Tract Infection Symptoms

    Time frame: 3 days (72 hours)

    >80% of patients treated with amikacin will have resolution of urinary tract infection symptoms.

Study contacts

Contact information is provided by the study sponsor or research team.

Antonios Likourezos, MA, MPH

CONTACT

[email protected]

718-283-6896

Reuben Strayer, MD

CONTACT

[email protected]

718-283-6000

Sponsors and collaborators

Lead sponsor

Antonios Likourezos

Other

Registry information

Official study title

Single Dose Amikacin for Uncomplicated Cystitis in the Emergency Department (ED): A Feasibility Study

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Feb 8, 2022
Registry last updated
Mar 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.